Advertisement
BRKR vs TMO
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Bruker Corporation (BRKR) reported Q2 2026 revenue of $838.5 million with 5.2% year-over-year growth and raised full-year guidance, though a goodwill impairment impacted GAAP results.
- Thermo Fisher Scientific (TMO) delivered stronger Q2 2026 organic revenue growth of 5% on $11.99 billion in sales and raised its full-year outlook, supported by broad end-market recovery.
- BRKR stock has shown higher volatility and larger year-to-date gains compared with TMO, reflecting its smaller market capitalization and exposure to specialized segments like semiconductors and fusion technology.
- TMO benefits from greater scale, recurring revenue streams, and recent portfolio optimization including the divestiture of its microbiology business and share repurchases.
- Both companies operate in the life sciences tools sector, with BRKR emphasizing advanced instrumentation and TMO offering a broader portfolio across analytical instruments, diagnostics, and biopharma services.
- Recent market sentiment has favored TMO due to consistent execution and raised guidance, while BRKR sentiment reflects mixed reactions to earnings beats alongside one-time charges.
Introduction
Bruker Corporation (BRKR) and Thermo Fisher Scientific (TMO) represent two prominent players in the life sciences and analytical instrumentation space. This comparison examines their recent performance, business models, and relative positioning amid evolving market conditions in the healthcare and technology sectors. Investors and traders focused on scientific tools, biopharma exposure, and growth-oriented equities may find this analysis relevant for assessing diversification opportunities or sector allocation decisions. The review draws on verifiable developments from recent weeks and months to highlight contrasts in scale, momentum, and risk profiles without forward-looking speculation.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) develops and manufactures scientific instruments and diagnostic tools serving life sciences, applied markets, pharmaceuticals, and biotechnology industries. In recent market activity, the company reported second-quarter 2026 revenue of $838.5 million, reflecting 5.2% year-over-year growth and a return to positive organic growth. Non-GAAP earnings per share reached $0.49, exceeding estimates, while full-year guidance was maintained or refined to $3.54–3.57 billion in revenue. Recent weeks have featured conference presentations and a collaboration with Luvata to supply superconductors for fusion power projects. Stock performance has included notable year-to-date appreciation alongside volatility tied to sector-specific demand in semiconductors and preclinical imaging, tempered by a one-time goodwill impairment charge affecting GAAP results.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) provides a comprehensive suite of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products with significant biopharma services exposure. During the most recent reporting period, the company posted second-quarter 2026 revenue of $11.99 billion, up 10% year over year with 5% organic growth, alongside adjusted earnings per share of $6.03 that surpassed expectations. Management raised full-year 2026 guidance, citing strengthening customer activity across end markets. Recent developments include the completion of the microbiology business divestiture, $1 billion in share repurchases, and introductions of next-generation platforms featuring advanced analytics. In recent weeks, the stock has demonstrated relative stability with gains supported by broad-based demand recovery and operational execution.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from a much larger library of hundreds of bots capable of trading thousands of different tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this trending roster. Available bots span a wide range of trading styles, strategies, timeframes, performance metrics, and ticker sets, with many showing varying win rates, drawdowns, and profitability statistics across different market regimes. This resource allows users to explore data-driven options suited to diverse objectives. Review the Trending AI Robots page for current selections and detailed statistics.
Head-to-Head Comparison
Bruker Corporation (BRKR) operates with a narrower focus on high-end instrumentation and specialized applications such as nuclear magnetic resonance and spatial biology, resulting in greater sensitivity to cyclical demand in areas like semiconductors. Thermo Fisher Scientific (TMO), by contrast, maintains broader diversification across instruments, consumables, diagnostics, and outsourced services, supporting more consistent recurring revenue. In recent momentum, TMO has exhibited steadier organic growth and raised guidance, while BRKR has delivered earnings beats offset by impairment charges and higher share-price volatility. Risk factors differ accordingly: BRKR faces exposure to niche technology cycles and smaller scale, whereas TMO contends with larger debt levels and integration of acquisitions. Sector sentiment has recently emphasized TMO’s execution amid improving biotech funding, creating a contrast in perceived stability versus BRKR’s higher-beta profile.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings delivery relative to guidance, and relative positioning within the life sciences tools sector, Tickeron’s AI models would currently assign a higher probabilistic preference to Thermo Fisher Scientific (TMO) over Bruker Corporation (BRKR). TMO’s broader revenue base, recent organic growth acceleration, and raised outlook provide measurable stability advantages, while BRKR’s performance reflects more variable catalysts tied to specific product cycles and one-time items.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Buy and TMO is a Buy.
BRKR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 92 | 60 | |
PRICE GROWTH RATING 1..100 | 36 | 25 | |
P/E GROWTH RATING 1..100 | 5 | 16 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for BRKR (61). This means that TMO’s stock grew somewhat faster than BRKR’s over the last 12 months.
TMO's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for BRKR (100). This means that TMO’s stock grew somewhat faster than BRKR’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as BRKR (92). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
TMO's Price Growth Rating (25) in the Medical Specialties industry is in the same range as BRKR (36). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as TMO (16). This means that BRKR’s stock grew similarly to TMO’s over the last 12 months.
| BRKR | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 65% |
| Stochastic ODDS (%) | 4 days ago 77% | 4 days ago 58% |
| Momentum ODDS (%) | 4 days ago 77% | 4 days ago 64% |
| MACD ODDS (%) | 4 days ago 73% | 4 days ago 66% |
| TrendWeek ODDS (%) | 4 days ago 71% | 4 days ago 62% |
| TrendMonth ODDS (%) | 4 days ago 75% | 4 days ago 62% |
| Advances ODDS (%) | 4 days ago 69% | 5 days ago 63% |
| Declines ODDS (%) | 6 days ago 74% | 21 days ago 62% |
| BollingerBands ODDS (%) | 4 days ago 70% | 4 days ago 64% |
| Aroon ODDS (%) | N/A | 4 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- BRKR’s TA Score: 5 bullish, 3 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а +4.63% price change this week, while TMO (@Medical Specialties) price change was +3.62% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.85%. For the same industry, the average monthly price growth was -7.27%, and the average quarterly price growth was -0.70%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.23%. For the same industry, the average monthly price growth was +8.55%, and the average quarterly price growth was +50.66%.
Reported Earning Dates
BRKR is expected to report earnings on Oct 29, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.85% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+2.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with BRKRP. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then BRKRP could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | +0.28% | ||
| BRKRP - BRKR | 90% Closely correlated | +0.52% | ||
| A - BRKR | 78% Closely correlated | -0.03% | ||
| MTD - BRKR | 75% Closely correlated | -0.49% | ||
| WAT - BRKR | 68% Closely correlated | +0.75% | ||
| RVTY - BRKR | 68% Closely correlated | +0.29% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -0.50% | ||
| A - TMO | 74% Closely correlated | -0.03% | ||
| DHR - TMO | 73% Closely correlated | +0.32% | ||
| RVTY - TMO | 70% Closely correlated | +0.29% | ||
| IQV - TMO | 69% Closely correlated | -1.69% | ||
| BRKR - TMO | 67% Closely correlated | +0.28% | ||
More | ||||